For healthcare and pharmaceutical companies, the accounting implications of disruption are closely linked to export logistics, product shelf-life, and counterparty risk. Given the regulated nature of the sector, these issues require careful evaluation at the reporting date and cannot be deferred in anticipation of future clarity.
Set out below are the key accounting areas requiring focused attention.
Revenue Recognition and Cut-off (Ind AS 115)
Revenue recognition for export shipments is a critical area, particularly where goods are in transit at the reporting date and delivery timelines may be affected.
Under Ind AS 115, revenue is recognised when control of goods transfers to the customer. In pharmaceutical transactions, this assessment is influenced not only by shipping terms but also by regulatory acceptance, product integrity, and delivery conditions.
Where shipments are subject to delays, rerouting, or extended transit risks, it is necessary to evaluate whether control has genuinely passed. For temperature-sensitive or regulated products, the risk of quality deterioration during transit may indicate that control has not transferred even if goods have been dispatched.
Cut-off testing therefore becomes particularly sensitive for shipments made close to the reporting date.
Inventory Valuation and Shelf-Life Risk (Ind AS 2)
The pharmaceutical sector faces a distinct inventory risk due to product shelf-life constraints. Delays in shipment or distribution can reduce the usable life of products or render them unsellable in regulated markets.
Ind AS 2 requires inventory to be measured at the lower of cost and net realisable value. Where reduced shelf-life affects expected selling price or usability, NRV may fall below cost, requiring write-downs.
This assessment should be performed batch-wise, considering expiry timelines, alternate marketability, and potential reprocessing or disposal costs.
Insurance Claims: Recognition vs Contingency
Logistics disruption may give rise to insurance claims for cargo delay, damage, or loss. The accounting treatment depends on the level of certainty regarding recovery.
A receivable should be recognised only when there is reasonable certainty of acceptance by the insurer. Until such confirmation is obtained, the claim should be treated as a contingent asset rather than recognised in the financial statements.
Expected Credit Loss on Receivables (Ind AS 109)
Receivables from distributors, hospitals, and institutional buyers in affected or higher-risk markets may require reassessment under the expected credit loss framework.
Ind AS 109 requires forward-looking estimation of credit losses. In such an environment, delays in payment cycles, funding constraints, or broader uncertainty may increase credit risk.
Companies should update their ECL models with appropriate overlays and ensure that assumptions reflect conditions as at the reporting date.
Other Aspects to Consider
• Contractual penalties and supply failures (Ind AS 37): Inability to meet supply commitments under tenders or hospital contracts may give rise to penalties or liquidated damages that require provisioning.
• Rebates, chargebacks, and pricing adjustments (Ind AS 115): Changes in supply patterns may affect rebate structures and pricing adjustments, which should be appropriately accounted for as reductions in revenue or liabilities.
• Cold-chain logistics costs: Additional handling and freight costs arising from delays should be accrued where incurred.
• Foreign exchange exposure (Ind AS 21): Export receivables and import payables should be remeasured at closing exchange rates.
• SEBI LODR disclosures: For listed entities, material financial or operational impacts must be disclosed in accordance with Regulations 30 and 33.
Closing Observation
For pharmaceutical companies, the current reporting period requires careful alignment between operational realities and financial reporting judgments. Revenue recognition, inventory valuation, and credit risk assessment are directly affected by conditions that may remain uncertain at the reporting date.
In this environment, robust documentation of assumptions and timely recognition of risks will be critical. It would be useful to understand how others in the sector are approaching these judgments in practice.
Uploaded On: 
Author: 
